Lilly’s Jaypirca moves closer to European approval for relapsed chronic lymphocytic leukemia
Eli Lilly and Company (Lilly) has moved one step closer to securing European approval for its targeted blood cancer therapy, Jaypirca (pirtobrutinib), after the European ... Read More
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion, marking a 32% increase from the previous ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
Lilly gets Jaypirca FDA approval for mantle cell lymphoma
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca ... Read More